GlassScriptPhysician profile
Joshua Stern
NPI 1326100686
$6,290.62
in general payments reported to CMS, 2019-2025
38 companies · $1,400 in 2025
The $1,400 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,036 · 2020: $349 · 2021: $507 · 2022: $1,392 · 2023: $762 · 2024: $845 · 2025: $1,400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,007.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,799.69 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Janssen Biotech, INC. | $1,164.30 | 2019-2025 | Stelara, Tremfya, Simponi |
| Pfizer INC. | $366.75 | 2019-2025 | |
| Gilead Sciences, INC. | $366.50 | 2019-2025 | Livdelzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $324.22 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $249.93 | 2019-2025 | Entyvio |
| Allergan, INC. | $231.08 | 2019 | |
| Celgene Corporation | $192.82 | 2021-2023 | Zeposia |
| Boston Scientific Corporation | $187.18 | 2020-2023 | Watchman Flx |
| Madrigal Pharmaceuticals | $150.00 | 2024 | Rezdiffra |
| E.R. Squibb & Sons, L.L.C. | $134.09 | 2022 | |
| Janssen Scientific Affairs, LLC | $125.00 | 2022 | |
| Chiesi USA, INC. | $101.32 | 2022-2023 | Cleviprex, Kengreal |
| Qol Medical, LLC | $84.95 | 2019-2023 | Sucraid |
| Merck Sharp & Dohme LLC | $64.78 | 2020-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $56.25 | 2024 | Voquezna |
| Genzyme Corporation | $53.54 | 2023-2025 | |
| Redhill Biopharma INC. | $50.26 | 2021-2023 | Talicia |
| Ipsen Biopharmaceuticals, INC | $50.00 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $47.62 | 2019-2025 | Suflave, Sutab |
| Novo Nordisk INC | $43.05 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $40.21 | 2022 | |
| Intercept Pharmaceuticals, INC. | $39.18 | 2019 | |
| Vivus LLC | $38.56 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $37.64 | 2022-2025 | |
| Romark Laboratories, Lc | $36.51 | 2019 | |
| Ucb, INC. | $32.06 | 2019-2021 | |
| Olympus America INC. | $30.41 | 2019 | |
| Biocon Biologics INC | $24.75 | 2025 | Yesintek |
| Abbott Laboratories | $22.15 | 2024 | Assurity |
| Ferring Pharmaceuticals INC. | $21.50 | 2021 | |
| Evoke Pharma, INC. | $21.15 | 2025 | |
| Davol INC. | $20.29 | 2020 | |
| Organon LLC | $18.23 | 2021-2023 | Hadlima |
| Lilly USA, LLC | $18.13 | 2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $17.47 | 2022 | |
| Micro-Tech Endoscopy USA, INC. | $16.61 | 2022 | |
| Daiichi Sankyo INC. | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Stern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.